首页 / 院系成果 / 成果详情页

Comment on "Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study" 期刊论文

编号：

7BAB509BF1CB9DE6F58213581C6201CE
作者：

Wang, Huikang#^[1,2,3,4,5]Xu, Xinjun#^[1,2,3,4,5]Song, Xicheng(宋西成)*^[1,2,3,4,5]Zhang, Yu(张宇)*^[1,2,3,4,5]
语种：

英文
期刊：

HEPATOLOGY INTERNATIONAL ISSN：1936-0533 2026 年 ; 2026 JAN 3
收录：
高质量科技期刊分级目录：

T3
推荐引用方式
GB/T 7714：

Wang Huikang,Xu Xinjun,Song Xicheng, et al. Comment on "Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study" [J].HEPATOLOGY INTERNATIONAL,2026.
APA：

Wang Huikang,Xu Xinjun,Song Xicheng,Zhang Yu.(2026).Comment on "Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study" .HEPATOLOGY INTERNATIONAL.
MLA：

Wang Huikang, et al. "Comment on "Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study"" .HEPATOLOGY INTERNATIONAL(2026).
入库时间：

1/9/2026 2:40:13 PM
更新时间：

2/4/2026 9:43:50 PM
条目包含文件：

文件类型： , 文件大小：

正在加载全文

未找到全文

浏览次数：13  下载次数：0

浏览次数：13

下载次数：0

打印次数：1